Michael Zand – Page 1056

Brainstorm Health: Obamacare Insurer Payments, OptiNose IPO, Spark Gene Therapy – Fortune

2017-10-13 Michael Zand NEWS

Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials – AJMC.com Managed Markets Network

Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy TrialsAJMC.com Managed Markets NetworkWhile many lung and bladder cancer patients respond well to immunotherapy, they eventually succumb to the disease because the immune system can no… Continue reading

2017-10-13 Michael Zand NEWS

No CRISPR for Sports – GenomeWeb

No CRISPR for SportsGenomeWebNew Scientist notes that the agency already prohibits the use of genetically modified cells and gene therapy and that the additional language appears to be aimed particularly at CRISPR-based gene editing. A WADA spokesperso… Continue reading

2017-10-13 Michael Zand NEWS

No CRISPR for Sports – GenomeWeb

2017-10-13 Michael Zand NEWS

Researchers learn more about toxic side effects of T-cell therapy pioneered at CHOP, Penn – Philly.com

Brainstorm Health: Obamacare Insurer Payments, OptiNose IPO, Spark Gene Therapy
Fortune
Happy Friday, Dailies. I thought I’d use this space today to highlight some great recent reporting by a couple of other dailies—you know, those things we used to call newspapers. Rolfe Winkler at the Wall Street Journal had a front-page eye-opener …

and more »

2017-10-13 Michael Zand NEWS

Editas Medicine, Inc. (NASDAQ:EDIT) Signals Intraday Volatility – Down by 6.47% – First News 24

Editas Medicine, Inc. (NASDAQ:EDIT) Signals Intraday Volatility – Down by 6.47%First News 24CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella … Continue reading

2017-10-13 Michael Zand NEWS

Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in Mice – Muscular Dystrophy News

Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in MiceMuscular Dystrophy NewsA new version of the CRISPR-Cas9 gene-editing technology called CRISPR-Gold has successfully restored the correct sequence of the dystrophin gene in a mouse… Continue reading

2017-10-13 Michael Zand NEWS

Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in Mice – Muscular Dystrophy News

2017-10-13 Michael Zand NEWS

1
…
1,054
1,055
1,056
1,057
1,058
…
3,823

Philly.com

Researchers learn more about toxic side effects of T–cell therapy pioneered at CHOP, Penn
Philly.com
The new cancer treatment, called CAR T-cell therapy, involves extracting immune cells called T cells from the patient, genetically modifying them to attack the cancer, and returning them to the patient’s body. One such treatment has been approved for …

Login

Cart

All posts by: Michael Zand

Brainstorm Health: Obamacare Insurer Payments, OptiNose IPO, Spark Gene Therapy – Fortune

Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials – AJMC.com Managed Markets Network

No CRISPR for Sports – GenomeWeb

No CRISPR for Sports – GenomeWeb

Researchers learn more about toxic side effects of T-cell therapy pioneered at CHOP, Penn – Philly.com

Editas Medicine, Inc. (NASDAQ:EDIT) Signals Intraday Volatility – Down by 6.47% – First News 24

Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in Mice – Muscular Dystrophy News

Advanced Gene-Editing Technology CRISPR-Gold Repairs DMD Mutation in Mice – Muscular Dystrophy News